Filter by: patients
What is N-Acetyl Glucosamine?

N-Acetyl-D-Glucosamine, or GlcNAc, or NAG) is a monosaccharide derivative of glucose. It has been proposed as a treatment for autoimmune diseases.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
MS (Multiple Sclerosis) 9 2 Efficacy_cant_tell
General health 1 0
Other 1 1 Efficacy_moderate
Hypermobility Syndrome 1 0
Increase effect of another treatment 1 0

See all 13 patients currently taking N-Acetyl Glucosamine

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
0
Mild
0
None
2

Reported Dosages

  100 mg daily 720 mg daily 750 mg daily 1,000 mg daily 1,500 mg daily 3,500 mg daily 4,000 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 5 Number of Patients: 5 1 Number of Patients: 1 3 Number of Patients: 3 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking N-Acetyl Glucosamine (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 1   Did not seem to work: 100%

See all 1 patient who’ve stopped taking N-Acetyl Glucosamine

Currently Taking N-Acetyl Glucosamine

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0

Stopped Taking N-Acetyl Glucosamine

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of N-Acetyl Glucosamine

Always
1 50%
Usually
1 50%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of N-Acetyl Glucosamine

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
2 100%

Cost

Paid out of pocket

Cost of N-Acetyl Glucosamine

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
1 100%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 28, 2012.